WO1997011719A3 - Administration stereoselective de composes chiraux - Google Patents

Administration stereoselective de composes chiraux Download PDF

Info

Publication number
WO1997011719A3
WO1997011719A3 PCT/GB1996/002371 GB9602371W WO9711719A3 WO 1997011719 A3 WO1997011719 A3 WO 1997011719A3 GB 9602371 W GB9602371 W GB 9602371W WO 9711719 A3 WO9711719 A3 WO 9711719A3
Authority
WO
WIPO (PCT)
Prior art keywords
stereoselective
delivery
chiral compounds
stereoisomer
excipient
Prior art date
Application number
PCT/GB1996/002371
Other languages
English (en)
Other versions
WO1997011719A2 (fr
Inventor
Charles M Heard
Keith R Brain
Kenneth Andrew Walters
Original Assignee
Univ Cardiff
An Ex Analytical Services Limi
Charles M Heard
Keith R Brain
Kenneth Andrew Walters
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9519517.8A external-priority patent/GB9519517D0/en
Application filed by Univ Cardiff, An Ex Analytical Services Limi, Charles M Heard, Keith R Brain, Kenneth Andrew Walters filed Critical Univ Cardiff
Priority to AU70906/96A priority Critical patent/AU7090696A/en
Publication of WO1997011719A2 publication Critical patent/WO1997011719A2/fr
Publication of WO1997011719A3 publication Critical patent/WO1997011719A3/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulation comprenant une matière biologiquement active présentant un premier et un second stéréoisomère ainsi qu'un excipient stéréosélectif. L'excipient stéréosélectif est capable de former sélectivement un complexe avec le premier stéréoisomère de sorte que, lors de l'administration à une membrane semi-perméable, le second stéréoisomère peut passer sélectivement à travers la membrane. Ceci a pour effet une activité biologique différentielle.
PCT/GB1996/002371 1995-09-25 1996-09-25 Administration stereoselective de composes chiraux WO1997011719A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU70906/96A AU7090696A (en) 1995-09-25 1996-09-25 Stereoselective delivery of chiral compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9519517.8 1995-09-25
GBGB9519517.8A GB9519517D0 (en) 1995-09-25 1995-09-25 Chiral delivery
GB9526478.4 1995-12-22
GBGB9526478.4A GB9526478D0 (en) 1995-09-25 1995-12-22 Chiral delivery

Publications (2)

Publication Number Publication Date
WO1997011719A2 WO1997011719A2 (fr) 1997-04-03
WO1997011719A3 true WO1997011719A3 (fr) 1997-07-31

Family

ID=26307817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/002371 WO1997011719A2 (fr) 1995-09-25 1996-09-25 Administration stereoselective de composes chiraux

Country Status (2)

Country Link
AU (1) AU7090696A (fr)
WO (1) WO1997011719A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62135450A (ja) * 1985-07-31 1987-06-18 Teijin Ltd 光学活性なベ−タ遮断薬の製造方法
EP0281951A1 (fr) * 1987-03-04 1988-09-14 Daicel Chemical Industries, Ltd. Dérivé d'alcoylphénylcarbamate de polysaccharide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62135450A (ja) * 1985-07-31 1987-06-18 Teijin Ltd 光学活性なベ−タ遮断薬の製造方法
EP0281951A1 (fr) * 1987-03-04 1988-09-14 Daicel Chemical Industries, Ltd. Dérivé d'alcoylphénylcarbamate de polysaccharide

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
(1986) 207 PP. AVAIL.: UNIV. MICROFILMS INT., ORDER NO. DA8705262 FROM: DISS. ABSTR. INT. B 1987, 48(1), 103, 1986 *
CHEMICAL ABSTRACTS, vol. 107, no. 16, 19 October 1987, Columbus, Ohio, US; abstract no. 141024, HAMADI, SALIM ABBAS: "Verapamil nasal drug delivery and stereoselective disposition in rats" XP002031511 *
CHEMICAL ABSTRACTS, vol. 122, no. 12, 20 March 1995, Columbus, Ohio, US; abstract no. 142100, HEARD, C. M. ET AL: "Mechanisms and implications of differential percutaneous permeation of chiral drugs" XP002031510 *
DATABASE WPI Section Ch Week 8730, Derwent World Patents Index; Class A96, AN 87-209297, XP002031512 *
DUDDU, SARMA P. ET AL: "Stereoselective dissolution of propranolol hydrochloride from hydroxypropyl methyl cellulose matrixes", PHARM. RES. (1993), 10(11), 1648-53 CODEN: PHREEB;ISSN: 0724-8741, 1993, XP002031509 *
HEARD C.M. ET AL.: "STEREOSELECTIVE ADSORPTION AND TRANS-MEMBRANE TRANSFER OF PRPANOLOL ENANTIOMERS USING CELLULOSE DERIVATIVES.", INT. J. PHARM., vol. 139, no. 1,2, 1996, pages 15-23, XP002031507 *
HEARD, C. M. ET AL: "In vitro skin penetration of propranolol enantiomers", INT. J. PHARM. (1993), 90(3), R5-R8 CODEN: IJPHDE;ISSN: 0378-5173, 1993, XP002031506 *
HEARD, CHARLES M. ET AL: "Does solute stereochemistry influence percutaneous penetration?", CHIRALITY (1995), 7(4), 305-9 CODEN: CHRLEP;ISSN: 0899-0042, 1995, XP002031505 *
KUNZ C.M. ET AL.: "STEREOSELECTIVE RELEASE OF RACEMIC DRUGS IN THE PRESENCE OF CHIRAL EXCIPIENTS.", PHARMACEUTICAL RESEARCH, vol. 11, no. 10SUP, 1994, pages S305, XP002031508 *
MAGGI, L. ET AL: "Evaluation of stereoselective dissolution of verapamil hydrochloride from matrix tablets press-coated with chiral excipients", INT. J. PHARM. (1996), 136(1,2), 43-51 CODEN: IJPHDE;ISSN: 0378-5173, 1996, XP002031504 *
PROC. INT. SYMP. CONTROLLED RELEASE BIOACT. MATER. (1994), 21ST, 447-8 CODEN: PCRMEY;ISSN: 1022-0178, 1994 *

Also Published As

Publication number Publication date
WO1997011719A2 (fr) 1997-04-03
AU7090696A (en) 1997-04-17

Similar Documents

Publication Publication Date Title
AU3310595A (en) Compositions and methods for identifying biologically active molecules
MXPA01011968A (es) Materiales y procesos para proporcionar pilas de combustibles y membranas activas.
CA2154424A1 (fr) 1-phenyl-3-dimethylaminopropane possedant des proprietes pharmaceutiques
CA2193337A1 (fr) Composes de type 1-phenyl-2-dimethylaminomethylcyclohexan-1-o1, ingredients pharmaceutiques actifs
KR20010012689A (ko) 혈액 정제용 폴리술폰형 중공사막 및 그의 제조 방법
WO1997014806A3 (fr) Administration de polypeptides biologiquement actifs
AU4950997A (en) Method for preparing malonate methylidene nanoparticles, nanoparticles optionally containing one or several biologically active molecules
EP0718030A3 (fr) Membranes composites à perméabilité élevée pour l'osmose inverse, leur procédé de fabrication, et procédé utilisant ces membranes
WO1995030523A3 (fr) Films plastiques retriturables
AU5505894A (en) Fermented bagasse feed, and its preparation and uses
CA2066618A1 (fr) Plasmides renfermant de l'adn encodant la sequence d'acides amines du tcf-ii, cellules transformees a l'aide des plasmides et methode de production de substances biologiquement actives a l'aide des cellules transformees
AU8359991A (en) Porous polysulfone media suitable for filtration
AU5668100A (en) Peptide conjugates for the stabilization of membrane proteins and interactions with biological membranes
AU7776887A (en) Novel aurebasidium sp. microorganisms, method for obtaining the same, and method for preparing erythritol with the same
DE60018564D1 (de) Funktionsfähige poly-alpha-aminosäurederivate zur modifizierung von biologisch wirksamen stoffen und deren herstellung
GB2331398A (en) Bearings and supports
DK0854879T3 (da) Nye forbindelser afledt af 5-0-desosamiyl-6-0-methyl-erythronolid A, fremgangsmåde til deres fremstilling og deres anvendelse til fremstilling af biologisk aktive stoffer
AU2380595A (en) Biologically active composition
ES2186240T3 (es) Uso de un producto liquido de fermentacion de carbohidratos en alimentos.
AU7552098A (en) Physiologically active substances tkr2449, process for producing the same, and microorganism
WO1997011719A3 (fr) Administration stereoselective de composes chiraux
AU4196999A (en) Rna channels in biological membranes
DE69217461D1 (de) Immobilisierte Enzym-Membran, immobilisierte Protein-Membran und Verfahren zu ihrer Herstellung
HUP9700074A3 (en) Low molecular yeast active substance extract and process for preparing the same
AU5143096A (en) Method for identifying biologically active substances by the ir effect on living cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA